Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors [0.03%]
M701（一种抗EpCAM×抗CD3双特异性抗体）的开发及临床试验：一种治疗晚期实体瘤癌性腹水的靶向腹腔内疗法
Rongrui Liu,Rongbo Lin,Ning Li et al.
Rongrui Liu et al.
Background: Malignant ascites (MA) is one of the major complications in advanced epithelial cancer patients and is associated with poor prognosis, poor quality of life, and severe symptoms. No efficient medicine is availa...
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies [0.03%]
体内CAR-T细胞工程：概念、研究进展、潜在挑战及增强策略
Yizhao Chen,Qianling Xin,Jiaqi Qiu et al.
Yizhao Chen et al.
After decades of development and accumulation, chimeric antigen receptor (CAR)-T therapy has become a revolutionary immunotherapy method, which has triggered changes in treatment methods and concepts in the fields of cancer, autoimmune diso...
Spatial ecostructural modelling of endometrial cancer identifies the key role of CD90 + CD105 + endothelial cells in tumour heterogeneity and predicts disease recurrence [0.03%]
空间生态结构模型揭示了子宫内膜癌中CD90+ CD105+ 内皮细胞在肿瘤异质性中的关键作用并预测疾病复发
Di Wu,Cinian Lv,Zhifeng Yan et al.
Di Wu et al.
Background: Current therapeutic strategies for endometrial cancer are mainly based on aggressive histological types and molecular subtypes. However, ignoring the spatial distribution of immune/stromal cells fails to accou...
Targeting platelet-tumor cell interactions via thromboxane A2-prostanoid receptor blockade to reduce metastasis in triple negative breast cancer [0.03%]
通过阻断血小板-肿瘤细胞相互作用中的 thromboxane a2 前列腺素受体来减少三阴性乳腺癌的转移
Veeresh Toragall,Ann C Rester,Salma Begum et al.
Veeresh Toragall et al.
In addition to their central role in blood hemostasis, it is increasingly clear that platelets contribute to multiple steps in the metastatic cascade. Platelets are one of the most abundant cells with which tumor cells interact once they en...
Immunotherapy for small cell lung cancer: current challenges and prospects [0.03%]
小细胞肺癌的免疫治疗：当前挑战与前景展望
Jiaxin Zhong,Guangling Jie,Haorui Qin et al.
Jiaxin Zhong et al.
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with limited treatment options. While immunotherapy has revolutionized SCLC therapy and now serves as a front-line treatment, the disease continues to present si...
Correction: Multi-model analysis of gallbladder cancer reveals the role of OxLDL-absorbing neutrophils in promoting liver invasion [0.03%]
订正：多模型分析发现氧化低密度脂蛋白吸收性中性粒细胞在促进肝内胆囊癌侵袭中的作用
Dongning Rao,Jiaxin Li,Mao Zhang et al.
Dongning Rao et al.
Published Erratum
Experimental hematology & oncology. 2025 Nov 5;14(1):129. DOI:10.1186/s40164-025-00722-8 2025
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution [0.03%]
采用单细胞分辨率解析核心结合因子急性髓系白血病患者的肿瘤异质性和克隆进化
Raphael Hablesreiter,Paulina M Strzelecka,Klara Kopp et al.
Raphael Hablesreiter et al.
Reconstructing and understanding intra-tumor heterogeneity, the coexistence of multiple genetically distinct subclones within the tumor of a patient, and tumor development is essential for resolving carcinogenesis and for identifying mechan...
Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming [0.03%]
乳酸和乳酸化在癌症中的作用：免疫抑制和微环境重塑的驱动因素
Xiaoyu Ji,Limin Xia
Xiaoyu Ji
Lactate, a key metabolite of the Warburg effect, plays a central role in shaping multiple hallmarks of cancer. Through lactate shuttling and engagement with specific receptors, it activates downstream signaling pathways that remodel the tum...
Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice [0.03%]
嵌合抗原受体修饰的造血干细胞(CAR-HSCs)使小鼠所有免疫细胞发挥抗肿瘤作用
Tao Wang,Ping Liu,Dongliang Zhang et al.
Tao Wang et al.
Chimeric antigen receptor T cell (CAR-T) is the main salvage therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). However, over 50% of patients relapse after CAR-T therapy. In this work, we transduced the CAR gene into hemat...
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer [0.03%]
新型的Mcl-1抑制剂pitavastatin能够克服三阴性乳腺癌细胞对紫杉醇耐药性
Dongmi Ko,Soeun Park,Minsu Park et al.
Dongmi Ko et al.
Background: Triple-negative breast cancer (TNBC) is notorious for its poor prognosis, high metastatic rates, and resistance to chemotherapy. We sought to investigate the anticancer effects of pitavastatin (PITA), a promis...